Top Page
GlaxoSmithKline
(LSE:GSK)
GlaxoSmithKline (GSK) vs. iShares MSCI United Kingdom ETF (EWC)
GlaxoSmithKline Business Overview & Revenue Model
GlaxoSmithKline Earnings Call Summary
GlaxoSmithKline Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 32.67B | 31.38B | 30.33B | 29.32B | 24.70B |
| Gross Profit | 23.70B | 21.90B | 21.25B | 19.46B | 16.34B |
| EBITDA | 11.88B | 6.67B | 9.14B | 8.63B | 6.45B |
| Net Income | 5.72B | 2.58B | 4.93B | 14.96B | 4.38B |
Balance Sheet | |||||
| Total Assets | 61.12B | 59.46B | 59.01B | 60.15B | 79.10B |
| Cash, Cash Equivalents and Short-Term Investments | 3.41B | 3.89B | 5.69B | 7.88B | 4.33B |
| Total Debt | 17.72B | 17.15B | 18.02B | 20.99B | 24.17B |
| Total Liabilities | 45.09B | 46.38B | 46.21B | 50.05B | 57.76B |
| Stockholders Equity | 16.38B | 13.67B | 13.35B | 10.60B | 15.05B |
Cash Flow | |||||
| Free Cash Flow | 5.96B | 3.57B | 4.42B | 5.14B | 5.02B |
| Operating Cash Flow | 7.30B | 6.55B | 6.77B | 7.40B | 7.95B |
| Investing Cash Flow | -5.85B | -1.23B | -1.59B | -8.77B | -1.78B |
| Financing Cash Flow | -1.63B | -4.73B | -5.64B | 823.00M | -7.59B |
GlaxoSmithKline Technical Analysis
GlaxoSmithKline Risk Analysis
GlaxoSmithKline Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | £223.35B | 28.13 | 23.00% | 1.53% | 10.20% | 40.57% | |
70 Outperform | £10.63B | 22.64 | 9.30% | 2.35% | 2.51% | 56.56% | |
69 Neutral | £80.59B | 12.93 | 37.19% | 3.29% | 2.73% | 119.38% | |
67 Neutral | £35.18B | 20.15 | 9.35% | 1.51% | -2.12% | 42.10% | |
59 Neutral | £2.81B | 11.21 | 15.83% | 4.16% | 3.73% | 27.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
GlaxoSmithKline Corporate Events
GSK plc has disclosed that its Non-Executive Chair, Sir Jonathan Symonds, purchased 2,500 ordinary shares of the company on 5 February 2026 on the London Stock Exchange at a price of £21.14 per share. The insider share purchase may be interpreted by investors as a signal of confidence from the company’s leadership in GSK’s prospects and long-term strategy, potentially supporting sentiment around the stock and the group’s positioning in the global biopharma sector.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £17.80 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has secured European Commission approval for its monoclonal antibody Nucala (mepolizumab) as an add‑on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils despite triple inhaled therapy. The green light, underpinned by positive phase III MATINEE trial data, makes Nucala the first and only monthly biologic in the EU evaluated across a broad COPD population with an eosinophilic phenotype and the first biologic to show pre‑specified phase III evidence of reducing exacerbations leading to emergency department visits and hospitalisations. In MATINEE, Nucala cut the annual rate of moderate and severe COPD exacerbations versus placebo on top of standard of care, with a safety profile comparable to placebo, reinforcing its role as a step‑up option for patients who remain highly symptomatic on inhaled triple therapy. The approval expands Nucala’s European label to a fifth indication and follows prior COPD approvals in the US, UK and China, strengthening GSK’s competitive position in respiratory biologics and potentially addressing a significant unmet need in a disease affecting around 40 million people in Europe and more than 390 million globally.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £17.80 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has disclosed share transactions involving senior personnel, as required under market regulations. David Redfern, President of Corporate Development, sold 100,000 ordinary shares in GSK at £21.09 each on 5 February 2026 on the London Stock Exchange, while Neil Falkingham, a person closely associated with Lynn Baxter, President Europe, sold 2,000 ordinary shares at £20.87 on the same date and venue, highlighting notable insider dealing activity that may draw investor attention to executive shareholding changes but does not in itself signal any change to the company’s operations or strategy.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £17.80 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK reported a strong 2025, with total sales rising 7% at constant exchange rates to £32.7 billion, driven by a 17% surge in Specialty Medicines, including double-digit growth in respiratory, immunology and inflammation, oncology and HIV, while vaccines and general medicines were broadly stable. Core operating profit grew 11% and core EPS 12%, supported by favourable product mix, SG&A efficiencies, higher royalty income and disciplined but increased R&D investment, while total operating profit and EPS more than doubled largely due to lower legal and credit charges. The company highlighted robust cash generation, sustained shareholder returns through an increased dividend and ongoing £2 billion share buyback, and reaffirmed its 2026 guidance for mid‑single digit sales growth and high‑single digit core profit and EPS growth, alongside a long‑term sales outlook of more than £40 billion by 2031. R&D momentum remained strong with five major FDA approvals in 2025, a bolstered pipeline in respiratory, immunology and oncology through acquisitions and partnerships, and expectations for further acceleration in 2026, including new approvals and pivotal trial readouts, positioning GSK to consolidate its competitive standing in high-value specialty and vaccine markets. An agreement with the US administration to lower prescription drug costs, in exchange for exemption from certain tariffs for three years, is factored into guidance and underscores the company’s efforts to balance US pricing pressure with market access and operational visibility for investors.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £19.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has disclosed that, as of 31 January 2026, its issued share capital comprises 4,316,103,805 ordinary shares, of which 240,019,489 are held in treasury, leaving 4,076,084,316 shares carrying voting rights. The updated voting rights figure provides investors and other market participants with the denominator needed to calculate disclosure thresholds for shareholdings under UK transparency rules, ensuring accurate reporting of significant interests in the company.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £19.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has secured European Commission approval to expand the use of its adjuvanted recombinant RSV vaccine, Arexvy, to all adults aged 18 and over, broadening access beyond earlier indications limited to older adults and those 50–59 at increased risk. The decision, which comes amid an estimated 158,000 RSV-related adult hospitalisations annually in the EU, strengthens GSK’s position in the fast-growing RSV vaccine market, supports its vaccines franchise, and sets the stage for further geographic expansion as the company pursues additional indications in major markets including the US and Japan.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £17.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has agreed to acquire California-based RAPT Therapeutics in a cash deal valuing the target’s equity at about $2.2 billion, netting GSK global rights (excluding Greater China) to ozureprubart, a long-acting anti-IgE monoclonal antibody in Phase IIb development for prophylactic protection against food allergens. The transaction, expected to close in the first quarter of 2026 via a tender offer at $58 per share followed by a merger, is designed to bolster GSK’s respiratory, immunology and inflammation pipeline and leverage its allergy-focused commercial infrastructure, as ozureprubart aims to offer 12‑weekly dosing and expand treatment eligibility in a growing food-allergy market that drives significant healthcare utilisation and economic burden in the US.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £16.75 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK and Japan’s Shionogi have agreed, together with Pfizer, to restructure the ownership of ViiV Healthcare, the specialist HIV company jointly created in 2009, in a move that consolidates control between the two remaining partners and removes Pfizer from the shareholder base. Under the deal, ViiV will issue new shares to Shionogi for $2.125 billion, raising Shionogi’s economic interest to 21.7% while GSK retains a 78.3% majority stake, and Pfizer’s 11.7% holding will be cancelled, with Pfizer receiving $1.875 billion and GSK a $250 million special dividend, subject to regulatory clearances expected by the first quarter of 2026. GSK will eliminate its Pfizer put option liability through retained earnings on completion, simplifying ViiV’s capital structure and giving Shionogi a larger economic stake alongside continued board representation, reinforcing the partners’ strategic focus on long-acting injectable HIV treatments and prevention and underscoring their commitment to expanding ViiV’s pipeline of next-generation integrase inhibitors.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £16.75 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has disclosed several transactions in which senior leaders, including non-executive director Dr Hal Barron, SVP and Group General Counsel James Ford, US President Maria Martinez-Davis and Chief Digital and Technology Officer Shobie Ramakrishnan, acquired GSK American Depositary Shares through the automatic reinvestment of dividends paid on 8 January 2026. The dividend reinvestment purchases, executed on the New York Stock Exchange on 9 and 14 January 2026 at prices around $50.22–$50.29 per ADS, incrementally increase insider holdings and signal continued alignment of top management and board members with shareholder interests.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £16.75 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc disclosed that President of Corporate Development David Redfern and Senior Vice President & Company Secretary Victoria Whyte have each acquired small numbers of GSK ordinary shares through the automatic reinvestment of dividends within individual savings accounts. The transactions, executed on 9 January 2026 on the London Stock Exchange at £18.845 per share, reflect routine dividend reinvestment by senior management rather than a strategic change in shareholding policy, but still underscore continued insider exposure to the company’s equity as required under market transparency rules.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £17.80 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc has disclosed a series of transactions in which senior executives and a person closely associated with one executive acquired small numbers of GSK ordinary shares through the automatic reinvestment of dividends paid on 8 January 2026 under the company’s Share Reward Plan. The reported dealings, which involved the CEO, regional and functional presidents, the group general counsel and a closely associated individual, were executed on the London Stock Exchange at a price of £18.9433 per share and reflect routine reinvestment activity rather than a strategic change in shareholding structure, but they do marginally increase insider equity alignment with other shareholders.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £16.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has secured European Commission approval for a new prefilled syringe presentation of its shingles vaccine Shingrix, which is already authorised in the EU for prevention of herpes zoster and post-herpetic neuralgia in adults at risk, marking an incremental innovation in its established vaccines franchise. The prefilled format, which will roll out across EU countries from 2026, is designed to simplify administration for healthcare professionals by eliminating the current two‑vial reconstitution process, potentially supporting broader and more efficient vaccination against a disease that affects around 1.7 million people annually in Europe and poses heightened risks for older adults and those with chronic conditions such as cardiovascular disease, diabetes and chronic kidney disease.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £16.60 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has reported positive topline data from its pivotal Phase III B-Well 1 and B-Well 2 trials of bepirovirsen, an investigational antisense oligonucleotide being developed as a finite, six‑month treatment for chronic hepatitis B (CHB), a condition affecting more than 250 million people and responsible for over half of global liver cancer cases. The trials, involving more than 1,800 patients across 29 countries, met their primary endpoint, showing statistically significant and clinically meaningful functional cure rates when bepirovirsen was added to current nucleos(t)ide analogue standard of care versus standard care alone, with even greater benefit in patients with lower baseline hepatitis B surface antigen levels and an acceptable safety profile; GSK plans global regulatory filings beginning in early 2026, positioning bepirovirsen as a potential first-in-class finite therapy and backbone for future sequential treatment strategies in hepatitis B, which could strengthen the company’s presence in hepatology and offer a major shift in long-term disease management for patients and healthcare systems.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £16.60 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has secured Japanese approval for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe or refractory bronchial asthma and chronic rhinosinusitis with nasal polyps, adding to prior clearances in the US and UK and a positive regulatory opinion in the EU. Based on phase III SWIFT and ANCHOR data showing that twice-yearly dosing significantly reduced asthma exacerbations and improved nasal polyp size and nasal obstruction while maintaining a placebo-like safety profile, the therapy offers a convenient, durable option that could ease disease burden for patients and lower strain on healthcare systems, bolstering GSK’s competitive position in high-value respiratory biologics.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £17.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc has disclosed that David Redfern, President of Corporate Development, and Victoria Whyte, Senior Vice President and Company Secretary, have each acquired 790 ordinary shares in the company through the exercise of options under GSK’s Share Save Plan. The options, originally granted in November 2022, were exercised on 2 January 2026 at a price of £11.39 per share on the London Stock Exchange, reflecting ongoing executive participation in the group’s employee share ownership schemes and aligning senior management further with shareholder interests.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £17.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has disclosed that, as of 31 December 2025, its issued share capital comprised 4,315,445,026 ordinary shares of 31¼ pence each, of which 240,019,489 are held in treasury. This leaves a total of 4,075,425,537 voting rights in the company, a key reference figure for investors monitoring or reporting changes in their shareholdings under UK financial transparency rules, and underscores GSK’s compliance with ongoing market disclosure obligations.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £17.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has secured approval from China’s National Medical Products Administration for its biologic Nucala (mepolizumab) as an add-on maintenance treatment for adults with chronic obstructive pulmonary disease characterised by elevated blood eosinophils, making it the first and only monthly biologic in China studied in a broad COPD population with blood eosinophil counts starting at 150 cells/µL. The decision, underpinned by positive phase III MATINEE and METREX trials showing statistically significant reductions in moderate and severe exacerbations and fewer hospitalisations versus standard care, strengthens GSK’s respiratory franchise in one of the world’s largest COPD markets, where about 100 million people are affected and COPD deaths account for more than 30% of global mortality, potentially expanding Nucala’s addressable patient base beyond its existing asthma and eosinophilic indications and reinforcing the company’s competitive positioning in biologic treatments for COPD worldwide.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £17.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has disclosed a series of director dealings in its equity, with multiple independent non-executive directors and a senior independent non-executive director purchasing ordinary shares and American Depositary Shares on 19 December 2025 across the London and New York stock exchanges. The coordinated insider buying, though involving relatively modest volumes, signals continued board-level confidence in the company’s prospects and aligns directors’ interests more closely with shareholders, a move that may be viewed positively by investors monitoring governance and insider activity in the pharmaceutical sector.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £17.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc has continued its share buyback programme, repurchasing 232,912 ordinary shares on 19 December 2025 through BNP Paribas at a volume-weighted average price of 1,807.58 pence, with the shares to be held in treasury. Since the start of the current buyback phase on 30 September 2025, GSK has acquired a total of 14,554,645 shares, lifting its treasury holding to 240,019,489 shares, equivalent to 5.89% of voting rights, and leaving 4,075,425,537 shares in issue, a move that modestly concentrates remaining shareholders’ stakes and signals ongoing capital-return efforts to the market.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £17.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has reached a voluntary agreement with the U.S. Administration to reduce the cost of its prescription medicines, particularly its extensive respiratory portfolio used by more than 40 million Americans with asthma and COPD, and to adopt a more balanced pricing strategy for new products across developed markets. The deal, which covers both GSK and its HIV-focused affiliate ViiV Healthcare, includes lower prices for certain Medicaid medicines, a direct purchasing platform offering up to 66% savings on most inhaled respiratory products, and participation in the Strategic Active Pharmaceutical Ingredients Reserve by securing a U.S. reserve of albuterol, while also providing both companies with clarity on future U.S. pricing rules and a three-year exclusion from s232 tariffs; these measures, combined with GSK’s previously announced $30 billion U.S. R&D and manufacturing investment plan and expansion of high-skilled jobs, are set to strengthen its U.S. footprint and support greater affordability and supply resilience for critical respiratory drugs.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £17.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc has repurchased 235,000 of its ordinary shares on 18 December 2025 via BNP Paribas SA as part of its ongoing share buyback programme, paying a volume‑weighted average price of 1,810.34p per share and holding the acquired stock as treasury shares. The latest transaction brings total repurchases since 30 September 2025 to 14,321,733 shares and leaves GSK with 239,786,577 shares in treasury and 4,075,654,506 shares in issue, with treasury shares now representing 5.88% of voting rights, information that helps investors gauge ownership dilution and voting power under UK disclosure and transparency rules.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £17.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced the recent purchase of 235,000 of its ordinary shares, as part of its ongoing share buyback program. The repurchased shares, with a volume-weighted average price of 1,841.56p per share, will be held in treasury. With this acquisition, GSK has maintained its commitment to enhancing shareholder value and now holds 239.55 million shares in treasury, while the total number of voting rights stands at approximately 4.08 billion. The initiative, supported by BNP Paribas as the broker, reflects GSK’s strategy to strengthen its financial position and optimize capital allocation.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £17.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) has announced the repurchase of 230,000 of its ordinary shares as part of its ongoing buyback program. The shares, purchased through BNP Paribas SA, will be held as treasury shares. This move is part of a broader strategy to manage the company’s capital structure and enhance shareholder value. Following this transaction, GSK holds a total of 239,316,577 shares in treasury, with a total of 4,076,124,506 shares in issue, excluding treasury shares. The buyback program reflects GSK’s commitment to returning value to shareholders and may influence the company’s market positioning by potentially increasing earnings per share.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £16.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced the FDA approval of Exdensur (depemokimab) for severe asthma with an eosinophilic phenotype, marking it as the first ultra-long-acting biologic with twice-yearly dosing. This approval, based on the SWIFT trials, showed significant reductions in asthma exacerbations and hospitalizations, potentially transforming patient care and reducing healthcare burdens. The approval could enhance GSK’s position in the respiratory market and offer a novel solution for the estimated 2 million Americans with severe asthma.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £16.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced the purchase of 230,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. The shares, bought at an average price of 1,825.73 pence, will be held as treasury shares, increasing GSK’s total treasury shares to 239,086,577. This move is part of a broader strategy to manage the company’s capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced the UK approval of Exdensur (depemokimab), the first ultra-long-acting biologic for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps. This approval, based on successful phase III trials, marks a significant advancement in respiratory treatment, offering twice-yearly dosing that reduces asthma exacerbations and hospitalizations. The approval is expected to alleviate healthcare burdens and improve patient outcomes, with further regulatory decisions anticipated in major markets like the US, Japan, EU, and China.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 230,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, which took place on December 12, 2025, is part of a broader strategy to manage the company’s capital structure and enhance shareholder value, with the shares being held as treasury shares. Following this purchase, GSK holds a total of 238,856,577 ordinary shares in treasury, representing 5.86% of the voting rights, which may influence shareholder decisions under regulatory guidelines.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of Nucala (mepolizumab) for treating chronic obstructive pulmonary disease (COPD) in patients with raised blood eosinophils. This recommendation is based on the MATINEE phase III trial, which demonstrated a significant reduction in COPD exacerbations with Nucala as an add-on to inhaled triple therapy. The approval could provide a new treatment option for millions of Europeans with uncontrolled COPD, potentially reducing hospitalizations and healthcare costs associated with the disease.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has given a positive opinion on depemokimab, a potential first ultra-long-acting biologic for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps in the EU. If approved, depemokimab, which requires only twice-yearly dosing, could significantly enhance treatment for millions of patients by reducing exacerbations and improving symptom control, marking a potential shift in respiratory disease management.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) has announced a transaction involving the purchase of 217,000 of its own ordinary shares, with prices ranging from 1,793.00p to 1,820.00p per share, as part of its ongoing buyback program. This move, executed through BNP Paribas SA, increases the company’s treasury shares to 238,626,577, while the total number of shares in issue remains at 4,076,812,560. The transaction reflects GSK’s strategy to manage its capital structure and enhance shareholder value, potentially impacting its market positioning and shareholder interests.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £1700.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced that its RSV vaccine, Arexvy, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, recommending its use for all adults aged 18 and older. This expansion could significantly impact the company’s market presence by addressing the high incidence of RSV-related hospitalizations in the EU, potentially reducing severe RSV disease in adults and enhancing GSK’s position in the vaccine industry.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £1700.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced that the US FDA approved Blujepa (gepotidacin), a new oral antibiotic for treating uncomplicated urogenital gonorrhoea, marking the first approval of a new antibiotic class for gonorrhoea in over three decades. This approval provides a new treatment option for patients who cannot use standard injectable antibiotics, addressing the urgent public health threat posed by Neisseria gonorrhoeae, a pathogen recognized by the WHO and CDC for its resistance to existing treatments. The approval follows successful phase III trials demonstrating the drug’s efficacy and safety, potentially impacting GSK’s market positioning in infectious diseases.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £1700.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc has announced the acquisition of ordinary shares by several key executives under the company’s Share Reward Plan. The transactions, which took place on December 9, 2025, involved the purchase of shares at a price of £18.0780 each, conducted on the London Stock Exchange. This move reflects the company’s commitment to aligning the interests of its leadership with those of its shareholders, potentially impacting the company’s operational strategies and market positioning positively.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £1700.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced the purchase of 220,000 ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction increases the company’s treasury shares to 238,409,577, while maintaining 4,077,029,560 shares in issue. The buyback is part of a strategic effort to manage capital and enhance shareholder value, reflecting GSK’s commitment to optimizing its financial structure.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £1700.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) announced the purchase of 250,000 of its own ordinary shares as part of its ongoing share buyback program. The shares were bought at prices ranging from 1,780.00p to 1,820.00p, with a volume-weighted average price of 1,800.43p. This transaction, executed through BNP Paribas SA, increases the total number of shares held in treasury to 238,189,577, representing 5.84% of the company’s voting rights. The buyback program is part of GSK’s strategy to enhance shareholder value and optimize its capital structure.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £1700.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced that its B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, has received Orphan Drug Designation from the US FDA for treating small-cell lung cancer (SCLC). This designation is based on early clinical data showing promising responses in patients with extensive-stage SCLC, a challenging cancer with limited treatment options. The designation marks the fifth regulatory recognition for risvutatug rezetecan, reinforcing GSK’s strategy to accelerate its development across various solid tumors, potentially enhancing treatment options for patients and strengthening GSK’s position in the oncology market.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £1700.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 229,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, part of a non-discretionary agreement, aims to optimize the company’s capital structure and potentially enhance shareholder value. Following this purchase, GSK holds 237,939,577 shares in treasury, with a total of 4,077,499,560 shares in issue, excluding treasury shares. The buyback program reflects GSK’s strategic financial management and could have implications for shareholder voting rights and market perception.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £17.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 248,000 of its own ordinary shares as part of its existing buyback program, executed through BNP Paribas SA. This transaction, which adds to the 12,245,733 shares already repurchased since September 2025, aims to optimize the company’s capital structure and may influence shareholder value by reducing the number of shares in circulation.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2049.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 233,000 of its own ordinary shares as part of its ongoing buyback program, facilitated through BNP Paribas SA. This transaction, which involved shares being bought at prices ranging from 1,819.00p to 1,852.50p, contributes to GSK’s strategic financial management by increasing the number of shares held in treasury to 237,462,577. This move is part of a broader effort to manage the company’s capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £1900.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced the purchase of 233,000 ordinary shares as part of its ongoing share buyback program, executed through BNP Paribas SA. This transaction is part of a broader strategy to manage its capital structure, with the company now holding 237,462,577 shares in treasury. The buyback is expected to enhance shareholder value and reflects GSK’s confidence in its financial health and future prospects.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £1900.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc has announced the purchase of 218,000 of its own ordinary shares as part of its ongoing share buyback program. These shares, acquired at prices ranging from 1,830.00p to 1,848.00p, will be held as treasury shares. This transaction is part of a non-discretionary agreement with BNP Paribas SA, and since September 2025, GSK has repurchased a total of 11,764,733 ordinary shares. This move is significant as it affects the company’s capital structure and could influence shareholder value by reducing the number of shares available in the market, potentially increasing earnings per share.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 200,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, which took place on December 2, 2025, is part of a larger strategy to manage its capital structure, with the company now holding over 237 million shares in treasury. The buyback program is expected to enhance shareholder value and reflects GSK’s confidence in its financial stability and future growth prospects.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £2000.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc has announced the repurchase of 203,000 of its ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. The shares, purchased at a volume-weighted average price of 1,800.44 pence, will be held as treasury shares. This transaction is part of a non-discretionary agreement with the broker, contributing to a total of 11,346,733 shares repurchased since September 2025. The move is aimed at optimizing the company’s capital structure and providing value to shareholders, with the current treasury shares accounting for 5.81% of the voting rights.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £2000.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the grant of options over Ordinary Shares as part of its Share Save Plan 2022. This transaction, involving key executives including James Ford, David Redfern, and Victoria Whyte, took place on November 28, 2025, at the London Stock Exchange, with each transaction priced at £14.19 for 643 shares. This move is indicative of GSK’s ongoing efforts to incentivize its leadership and align their interests with company performance.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £2000.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 250,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas. This transaction, conducted on November 28, 2025, is part of a larger strategy to manage the company’s capital structure and enhance shareholder value. Following this purchase, GSK holds 236,608,577 shares in treasury, with a total of 4,078,825,107 shares in issue. The buyback program is a strategic move to optimize the company’s financial position and potentially increase the value of its remaining shares.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £2000.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the repurchase of 245,000 of its ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This move is part of a broader strategy to manage the company’s capital structure and enhance shareholder value. Following this transaction, GSK holds a total of 236,358,577 shares in treasury, with the total number of voting rights in the company standing at 4,079,073,350. The buyback program reflects GSK’s commitment to returning value to shareholders and maintaining a flexible balance sheet.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £2000.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the repurchase of 170,733 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction is part of a broader strategy to manage the company’s capital structure and enhance shareholder value, with the shares being held as treasury shares. Following this purchase, GSK holds 236,113,577 shares in treasury, representing 5.79% of the voting rights, which could influence shareholder decisions and market perceptions.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £2000.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 170,000 of its own ordinary shares as part of its ongoing buyback program, with shares acquired through BNP Paribas SA. The shares will be held as treasury shares, and this transaction contributes to the company’s strategy to manage its capital structure and return value to shareholders. The buyback program, initiated on 30 September 2025, has seen GSK purchase a total of 10,478,000 shares. This move is expected to impact the company’s voting rights and shareholding structure, with 5.78% of voting rights now attributable to treasury shares.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £2000.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the repurchase of 170,000 of its ordinary shares as part of its ongoing buyback program, with shares purchased at prices ranging from 1,775.50p to 1,793.50p. This transaction, executed through BNP Paribas SA, increases the total number of shares held in treasury to 235,772,844, representing 5.78% of the company’s voting rights. The buyback program aims to optimize the company’s capital structure and return value to shareholders, potentially impacting market perceptions and shareholder interests.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £16.60 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the purchase of 180,000 of its own ordinary shares as part of its ongoing buyback program. The shares, acquired at a volume-weighted average price of 1,766.33 pence, will be held as treasury shares. This transaction, facilitated through BNP Paribas SA, contributes to the total of 10,138,000 shares repurchased since the program’s announcement on 30 September 2025. Following this purchase, GSK holds 235,602,844 shares in treasury, with a total of 4,079,829,083 shares in issue, excluding treasury shares. This buyback effort is part of GSK’s strategy to manage its capital structure and return value to shareholders.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £21.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 360,000 of its ordinary shares as part of its ongoing buyback program. This transaction, executed through BNP Paribas, reflects GSK’s strategy to manage its capital structure and enhance shareholder value. Following this purchase, GSK holds 235,422,844 shares in treasury, with a total of 4,080,008,266 shares in issue, impacting the voting rights and shareholding structure.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £21.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
TESARO, a subsidiary of GSK, has initiated litigation against AnaptysBio, Inc. in the Delaware Chancery Court, alleging a breach of the license agreement concerning the oncology treatment Jemperli (dostarlimab). This legal action seeks to terminate the current license agreement, secure a perpetual license for dostarlimab, and reduce royalties and milestone payments to AnaptysBio by 50%. Jemperli, approved in over 35 countries for endometrial cancer, has seen significant growth due to label expansions, with ongoing clinical trials exploring its use in other cancers. This litigation could impact GSK’s operations and market positioning in oncology treatments.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £21.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) has announced the purchase of 243,000 of its own ordinary shares as part of its ongoing share buyback program. The shares, acquired through BNP Paribas SA, will be held as treasury shares, increasing the company’s total treasury shares to 235,062,844. This move is part of a non-discretionary agreement with the broker and reflects GSK’s strategy to manage its capital structure effectively. The transaction impacts the voting rights percentage of the company, which shareholders can use to assess their interests under regulatory guidelines.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £21.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc has announced the purchase of 185,000 of its ordinary shares as part of its ongoing share buyback program. The shares, acquired through BNP Paribas SA, will be held as treasury shares, increasing the total number held to 234,819,844. This transaction is part of a non-discretionary agreement aimed at enhancing shareholder value and optimizing the company’s capital structure.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2087.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the acquisition of American Depositary Shares (ADSs) by Dr. Hal Barron, a Non-Executive Director, and James Ford, SVP and Group General Counsel, through the reinvestment of dividends in their respective savings plans. These transactions, conducted on the New York Stock Exchange, reflect the company’s ongoing commitment to aligning executive interests with shareholder value.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2087.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) announced the repurchase of 170,000 ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, conducted on November 17, 2025, involved shares purchased at prices ranging from 1,781.00p to 1,800.50p, with an average price of 1,789.39p. The repurchased shares will be held as treasury shares, contributing to a total of 256,634,844 shares in treasury. This move is part of GSK’s strategy to manage its capital structure and return value to shareholders, reflecting confidence in its financial health and future prospects.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £15.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) has announced the purchase of 170,000 of its own ordinary shares as part of its ongoing buyback program. This transaction, conducted through BNP Paribas, is part of a larger strategy to manage the company’s capital structure and return value to shareholders. Following this purchase, GSK holds a total of 256,464,844 shares in treasury, with 4,058,966,266 shares remaining in issue. The buyback program reflects GSK’s confidence in its financial health and commitment to enhancing shareholder value.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £15.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the repurchase of 167,000 of its own shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction is part of a larger strategy initiated on September 30, 2025, which has seen the company buy back a total of 8,830,000 shares. The repurchased shares will be held as treasury shares, impacting the company’s voting rights and share distribution, with 6.31% of voting rights now attributable to treasury shares. This move reflects GSK’s efforts to manage its capital structure and return value to shareholders.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £15.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the acquisition of ordinary shares by several of its senior executives, including the CEO and CFO, under the company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, highlights the company’s commitment to aligning the interests of its leadership with those of its shareholders, potentially strengthening stakeholder confidence in GSK’s strategic direction.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £15.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 167,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, which took place on November 12, 2025, is part of a larger initiative that has seen the company repurchase 8,663,000 shares since September 30, 2025. The repurchased shares will be held as treasury shares, and the total number of voting rights in the company remains at 4,059,300,530. This move is expected to impact the company’s financial structure and shareholder value, reflecting GSK’s strategic focus on optimizing its capital allocation.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £15.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) plc has announced the purchase of 167,000 of its own ordinary shares, as part of its ongoing share buyback program. The shares, purchased through BNP Paribas SA, will be held as treasury shares. This transaction is part of a larger buyback initiative that has seen the company acquire 8,496,000 shares since September 30, 2025. The buyback program is designed to optimize the company’s capital structure and potentially enhance shareholder value by reducing the number of shares outstanding.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £15.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) has announced a recent purchase of 170,000 of its own ordinary shares as part of its existing buyback program. This transaction, executed through BNP Paribas SA, reflects GSK’s strategy to manage its capital structure effectively by holding these shares in treasury. Following this purchase, GSK now holds 255,793,844 ordinary shares in treasury, with a total of 4,059,634,530 shares in issue. This move is part of a broader buyback initiative that has seen the company acquire over 8 million shares since late September 2025, potentially impacting shareholder value and market perception.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £15.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc has announced provisional dividend dates for the year 2026, outlining key dates for ordinary shares and American Depositary Shares. These dates are subject to change and provide stakeholders with a timeline for dividend-related activities, reflecting GSK’s commitment to maintaining transparency and shareholder engagement.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £15.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced the purchase of 170,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, part of a non-discretionary agreement, brings the total number of shares held in treasury to 255,623,844, with 4,059,804,530 shares remaining in issue. The buyback program is designed to optimize the company’s capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £15.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 170,000 of its own ordinary shares as part of an ongoing buyback program, facilitated through BNP Paribas. This transaction is part of a larger strategy initiated on September 30, 2025, which has seen the company acquire a total of 7,989,000 shares. These shares will be held in treasury, impacting the total number of voting rights and potentially influencing shareholder interest calculations under regulatory guidelines.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £15.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc has announced the purchase of 170,000 of its own ordinary shares as part of its ongoing buyback programme, facilitated through BNP Paribas SA. This move increases the company’s treasury shares to 255,283,844, while the total number of voting rights remains at 4,060,139,755. The buyback is part of a strategic effort to manage the company’s capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £22.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.